GlobeNewswire Inc.··Sapu Nano / Oncotelic TherapeuticsSapu Nano Advances mTOR Therapy With First Patient in Everolimus IV Trial
Sapu Nano dosed first patient in Phase 1b trial of intravenous everolimus formulation for advanced cancers including breast cancer and renal cell carcinoma.
OTLCbreast cancerneuroendocrine tumors